[1] X. Xu, Q. Sun, X. Yu, et al. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy[J]. Virus research, 2017, 233: 35-41. [2] J. Qian, J. Ding, R. Yin, et al. Newcastle disease virus-like particles induce dendritic cell maturation and enhance viral-specific immune response[J]. Virus Genes, 2017: 1-10. [3] C. Ou, Q. Wang, Y. Yu, et al. Chemokine receptor CCR5 and CXCR4 might influence virus replication during IBDV infection[J]. Microbial Pathogenesis, 2017, 107: 122-128. [4] N. A. Ciccone, L. P. Smith, W. Mwangi, et al. Early pathogenesis during infectious bursal disease in susceptible chickens is associated with changes in B cell genomic methylation and loss of genome integrity[J]. Developmental Comparative Immunology, 2017, 73: 169-174. [5] C. Panousis, U. Dhagat, K. M. Edwards, et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common beta chain of the IL-3, GM-CSF and IL-5 receptors[J]. MAbs-Austin, 2016, 8(3): 436-453. [6] S.-H. Kim, S. Chen, X. Jiang, et al. Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein[J]. Journal of Virology, 2015, 484: 163-169. [7] D. H. Lawson, S. Lee, F. Zhao, et al. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)[J]. Journal of Clinical Oncology, 2015, 33(34): 4066-4076. [8] N. Jiang, Z. Tian, J. Tang, et al. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Downregulates the Expression of Protumor Factors Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in a GM-CSF Receptor-Independent Manner in Cervical Cancer Cells[J]. Mediators of Inflammation, 2015, 2015: 601-604. [9] H. Cheng, A. Wang, J. Meng, et al. Enhanced metastasis in RNF13 knockout mice is mediated by a reduction in GM-CSF levels[J]. Protein Cell, 2015, 6(10): 746-756. [10] P. Bhattacharya, I. Budnick, M. Singh, et al. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy[J]. Journal of Interferon Cytokine Research, 2015, 35(8): 585-599. [11] H. Zhang, P. Qian, B. Peng, et al. A novel subunit vaccine co-expressing GM-CSF and PCV2b Cap protein enhances protective immunity against porcine circovirus type 2 in piglets[J]. Vaccine, 2015, 33(21): 2449-2456. [12] R. Xu, S. Megati, V. Roopchand, et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines[J]. Vaccine, 2008, 26(37): 4819-4829. [13] P. Chambers, N. S. Millar, R. W. Bingham, et al. Molecular Cloning of Complementary DNA to Newcastle Disease Virus, and Nucleotide Sequence Analysis of the Junction between the Genes Encoding the Haemagglutinin-Neuraminidase and the Large Protein[J]. Journal of General Virology, 1986, 67(3): 475-486. [14] H. Liu, P. Zhang, P. Wu, et al. Phylogenetic characterization and virulence of two Newcastle disease viruses isolated from wild birds in China[J]. Infection, Genetics and Evolution, 2013, 20: 215-224. [15] S. Hu, H. Ma, Y. Wu, et al. A vaccine candidate of attenuated genotype VII Newcastle disease virus generated by reverse genetics[J]. Vaccine, 2009, 27(6): 904-910. [16] V. Palya, T. Tatár-Kis, T. Mató, et al. Onset and long-term duration of immunity provided by a single vaccination with a turkey herpesvirus vector ND vaccine in commercial layers[J]. Veterinary Immunology and Immunopathology, 2014, 158(1–2): 105-115. [17] M. Farooq, U. Saliha, M. Munir, et al. Biological and genotypic characterization of the Newcastle disease virus isolated from disease outbreaks in commercial poultry farms in northern Punjab, Pakistan[J]. Virology Reports, 2014, 3: 30-39. [18] Z. Tao, H. Yang, D. Jia, et al. Molecular cloning, recombinant expression and characterization of GMCSF from the rhesus monkey, Macaca mulatta[J]. Developmental Comparative Immunology, 2013, 40(1): 69-77. [19] P. T. Loudon, E. J. Yager, D. T. Lynch, et al. GM-CSF Increases Mucosal and Systemic Immunogenicity of an H1N1 Influenza DNA Vaccine Administered into the Epidermis of Non-Human Primates[J]. PLoS One, 2010, 5(6): 110-121. [20] 王黎霞, 徐赓, 王彩霞, 等. 粒细胞-巨噬细胞集落刺激因子(GM-CSF)基因的克隆、原核表达及生物活性鉴定[J]. 中国兽医学报, 2010, 30(7): 912-916. [21] 谭兵, 王红宁, 张毅, 等. 鸡粒细胞-巨噬细胞集落刺激因子的原核表达及生物学活性分析[J]. 畜牧兽医学报, 2009, 40(5): 725-729. [22] B. Tan, H. Wang, L. Shang, et al. Coadministration of chicken GM-CSF with a DNA vaccine expressing infectious bronchitis virus (IBV) S1 glycoprotein enhances the specific immune response and protects against IBV infection[J]. Archives of Virology, 2009, 154(7): 1117-1124. [23] 于新友, 赵蕾, 孙翠萍, 等. 白来杭鸡IL-18和GM-CSF基因克隆与序列分析[J]. 中国动物传染病学报, 2011, 19(3): 28-33. [24] 窦永喜, 才学鹏, 景志忠. 猪粒细胞-巨噬细胞集落刺激因子基因的克隆、序列分析及蛋白结构预测[J]. 中国预防兽医学报, 2005, 27(6): 474-482.
|